Tuberculosis (TB) blood culture tests will require FDA clearance
This article was originally published in Clinica
Automated blood culturing systems used in disease diagnosis must obtain US premarket notification clearance from October 25th, 1995. The FDA says it is revoking the exemption from 510(k) requirements for these devices because of significant questions of safety and effectiveness. It cites the reported failure of devices used in detecting Mycobacterium tuberculosis.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.